A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
← catalyst calendarNCT07787169 · readout ≤ 704 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Double · Screening
Enrollment
179estimated
Sites
10
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-26
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Sep 2026 | estimated | When the study began enrolling |
| Primary completion | Jul 2028 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Alzheimer Disease
- Amyloid
- Plaque, Amyloid
- Healthy Volunteers
Interventions
- Drug: LY4405094
- Drug: LY4405094
- Drug: Placebo
- Drug: Placebo
- Other: Florbetapir F18
- Other: Florbetaben F 18
Primary outcome
what the primary-completion date above is the date OFThe number of participants allocated to each substudy
measured Baseline up to Day 160
Related
LLY · their whole pipeline · Alzheimer's Disease readouts · Congress trades in LLY · Executive-branch trades in LLY
LLY's other studiesmost recently updated first
- A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2) Phase 3 · Active, not recruiting
- A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease Phase 1 · Not yet recruiting
- A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults Phase 3 · Recruiting
- A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7) Phase 2 · Recruiting
- A Study of the Effects of Itraconazole on LY4395089 in Healthy Participants Phase 1 · Completed
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed